| Similar Articles |
|---|
 |
The Motley Fool
November 5, 2007
Brian Lawler |
Follow the Trend With Novo Nordisk The future is bright for Danish drugmaker Novo Nordisk. The worldwide leader in diabetes treatments turns in another good quarter.   |
The Motley Fool
August 8, 2008
Brian Lawler |
Not Bad, Novo Nordisk The drugmaker's performance is better than its numbers suggest. |
The Motley Fool
October 31, 2006
Brian Lawler |
Novo Nordisk Still Knows Sales There's more competition in diabetes care now, but the Danish pharmaceutical is thriving. Investors, take note. |
The Motley Fool
April 30, 2008
Brian Lawler |
A Dominating Danish Drugmaker Novo Nordisk turns in solid first-quarter financial numbers. |
The Motley Fool
October 31, 2008
Brian Orelli |
Disease Is Good for Novo Nordisk The Danish drugmaker is able to grow despite the Danish krone moving against the currencies that predominate its sales.. |
The Motley Fool
January 31, 2007
Brian Lawler |
Novo Nordisk Knows Sales Growth Diabetes care leads the way for this Danish drugmaker. Investors willing to do a little extra financial sleuthing will find a pharmaceutical company that's the global leader in a rapidly growing health-care segment. |
The Motley Fool
August 12, 2005
Stephen D. Simpson |
Novo Nordisk Perks Up This leading insulin company rebounds from a sluggish first quarter. For investors willing to buy and hold a stock for years, Novo Nordisk could still be an interesting play on a serious and growing disease market. |
The Motley Fool
January 27, 2006
Stephen D. Simpson |
Challenges Needle Novo Nordisk The insulin franchise is attractive, but under threat. Guidance for 2006 wasn't impressive and there are definite challenges ahead. Investors, take note. |
The Motley Fool
June 27, 2008
Brian Lawler |
This Drug Market Is Booming One therapeutic category seems to be expanding significantly faster than most of its peers, the one that helps the unfortunately burgeoning number of diabetics in the U.S. and worldwide. |
The Motley Fool
January 28, 2005
Stephen D. Simpson |
An Understated Scandinavian The Danish pharmaceutical may not be quite cheap enough to be a true value, but investors looking for a solid growth stock should see what's new with Novo Nordisk. |
The Motley Fool
September 30, 2008
Brian Lawler |
Novo Nordisk Takes On All Comers Its diabetes franchise is about to get bigger. |
Chemistry World
September 24, 2012
Andrew Turley |
$100m of diabetes R&D in China Danish drug maker Novo Nordisk has announced plans to invest $100 million in its R&D site in Beijing, China. The move will create 130 -- 200 new research jobs. |
The Motley Fool
October 27, 2005
Stephen D. Simpson |
What's New With Novo? Novo Nordisk is a good play on diabetes, but will new drugs reduce the need for insulin? Investors, take note. |
The Motley Fool
June 9, 2008
Brian Lawler |
Novo Nordisk's Daring Success Novo Nordisk's potential blockbuster compound excels in late-stage head-to-head testing. Investors, take note. |
The Motley Fool
June 13, 2008
Brian Lawler |
Novo Nordisk Bleeds a Little The pharmaceutical's hot streak ends as a vital study fizzles out. |
Chemistry World
November 9, 2010
Andrew Turley |
Company snapshot: Novo Nordisk As the results for the third quarter of this year roll in, one pharma major - Danish company Novo Nordisk - seems to have done better than most with its diabetes medicines. |
The Motley Fool
January 16, 2008
Brian Lawler |
Another Inhalable Insulin Bites the Dust Novo Nordisk discontinues development of its troubled diabetes treatment and settles its patent infringement lawsuit against Pfizer. Investors, take note. |
The Motley Fool
September 30, 2011
Brian Orelli |
A Drug Market That's 366 Million Strong Diabetes drugs have potential. |
The Motley Fool
June 24, 2008
Brian Orelli |
A Diabetes Drug Delivery Deal Several pharmaceutical companies compete to deliver a diabetes medication that can be taken orally or once-weekly. |
The Motley Fool
January 31, 2007
Brian Lawler |
No Sickness for Amylin Sales of the drugmaker's type-2 diabetes drugs showed solid growth. Investors, take note. |
The Motley Fool
November 24, 2010
Brian Orelli |
Profit From the United States of Diabetes Half the country could have an early form by 2020. |
Chemistry World
June 16, 2014
Phillip Broadwith |
Novo Nordisk to create 6000 jobs by 2022 Danish insulin and diabetes specialist Novo Nordisk says it intends to employ 6000 more highly skilled workers within Denmark by 2022. Half of these new staff will work in R&D. |
The Motley Fool
October 2, 2009
Brian Orelli |
Warning! Potential Blockbuster Ahead It's a little early to call it, but it looks like Bristol-Myers Squibb and AstraZeneca have a potential blockbuster on their hands with their new diabetes drug. |
BusinessWeek
April 30, 2010
Drew Armstrong |
The Lobbying for Death by Diabetes How a health-reform provision may help spur sales of insulin. |
The Motley Fool
July 22, 2009
Brian Orelli |
The Blockbuster Around the Corner Amylin Pharmaceuticals' Byetta sales are improving, but is it enough? |
The Motley Fool
June 18, 2010
Brian Orelli |
Hot Dog! No Competition for Now Roche's diabetes pipeline drug is delayed. |
The Motley Fool
April 28, 2005
Stephen D. Simpson |
Novo Nordisk Could Use a Boost Investors reacted badly to first-quarter results, but there's still a lot to like about the Danish pharmaceutical. |
Chemistry World
September 3, 2014
Phillip Broadwith |
Novo Nordisk quits inflammation R&D and cuts jobs Novo Nordisk is terminating its inflammatory disease R&D programs after the company's leading rheumatoid arthritis drug candidate failed in clinical trials. |
The Motley Fool
April 30, 2011
Brian Orelli |
No Long-Term Guidance? No Problem! Looking good, Merck. |
The Motley Fool
October 22, 2008
Brian Orelli |
Why Amylin Skipped Some Byetta Numbers Usually the company presents the individual sales numbers for its two diabetes drugs from the year-ago quarter for investors to compare. But this time they were conspicuously absent. |
The Motley Fool
February 28, 2007
Brian Lawler |
No Dice for Novo Novo Nordisk reports a failed clinical trial for one of its top drugs. Shares were down more than 5% on the news. |
The Motley Fool
July 8, 2008
Brian Lawler |
Blockbuster Drugs Bound for Extinction? One of the biggest classes of prescription drugs, those for diabetes treatments, faces tougher FDA standards. |
The Motley Fool
June 23, 2010
Brian Orelli |
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. |
The Motley Fool
June 2, 2010
Brian Orelli |
Take Your Low Margins and Shove 'Em In an effort to help lower its budget problems, Greece told drugmakers it was slashing prices of drugs, take it or leave it. Novo Nordisk chose "leave it." |
The Motley Fool
January 26, 2010
Brian Orelli |
Is Victoza's Victory in Vain? Novo Nordisk finally gets the FDA to sign off on its once-daily diabetes drug. |
The Motley Fool
July 22, 2010
Brian Orelli |
It's All About the Future for Amylin Its second quarter stank, but there's a lot up ahead. |
The Motley Fool
June 29, 2010
Brian Orelli |
Diabetes Drug Development Pops and Drops When companies present at a major meeting, there's bound to be both. |
Managed Care
June 2007 |
Seventy Percent Surge In Diabetes Spending Spending on endocrine and diabetes therapies could surge nearly 70% in the next two years, according to research. Diabetes treatments were the second leading contributor in total dollars to prescription drug spending growth in 2006. |
The Motley Fool
July 22, 2008
Brian Orelli |
Anemic Amylin's Signs of Recovery Sales of Amylin Pharmaceuticals' diabetes drug Byetta have slowed over the last few quarters, but the company seems to be turning things around. |
The Motley Fool
August 21, 2007
Brian Orelli |
Sweet Phase 3 Data Although diabetes drugs have come under fire lately, insulin maker Novo Nordisk is moving full steam ahead with its newest drug to help fight type 2 diabetes. |
The Motley Fool
November 21, 2007
Brian Orelli |
Phase 2 Data to Sink Your Teeth Into Novo Nordisk releases encouraging phase 2 clinical data about its weight-loss/diabetes drug, liraglutide. Investors, take note. |
The Motley Fool
April 16, 2010
Brian Orelli |
It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet. |
The Motley Fool
June 8, 2009
Brian Orelli |
For the RECORD... Avandia's not going to make a comeback for GlaxoSmithKline. |
The Motley Fool
May 20, 2009
Brian Orelli |
Joining to Treat, and Beat, Diabetes Medical-device maker Medtronic and drugmaker Eli Lilly are teaming up to co-promote the companies' diabetes products to doctors and patients. |
The Motley Fool
June 30, 2011
David Williamson |
Biotech Takes On the Next Big Problem The news coming out of this week's annual conference of the American Diabetes Association wasn't good. |
Pharmaceutical Executive
October 1, 2005 |
Changing Diabetes An interview with Novo Nordisk's president of U.S. operations Martin Soeters on how a nation that leads the world in diabetes research does such a poor job of treating it. Here, he offers some solutions. |
The Motley Fool
June 11, 2008
Brian Orelli |
Amylin's Down and Up on Diabetes Investors may be over-reacting to news both good and bad from Amylin Pharmaceuticals. |
The Motley Fool
July 19, 2007
Brian Orelli |
Head to the U.S. to Sue Your Neighbor Danish Novo Nordisk and French Sanofi-Aventis fight over insulin-delivery systems. Since the patent covers the U.S., the two companies will need to fight it out in U.S. courts. |
The Motley Fool
March 5, 2008
Brian Orelli |
FDA (Indirectly) Thwacks Amylin The FDA's draft guidance puts a cloud of uncertainty over the makers of diabetes drugs. |
The Motley Fool
September 20, 2010
Brian Orelli |
Potential Blockbuster, No Me-Too About It A diabetes-fighting duo do it right this time. |
